Skip to main navigation Skip to main content
Home
Menu
  • Join Our Mailing List
  • Contact Us
  • About
    • About BBCIC
      • BBCIC FAQs
    • Governance
      • Board of Managing Directors
      • Communications Committee
      • Steering Committee
      • Science Committee
    • Partners
    • Contact
  • Research
    • Approach
    • Range of Research
    • Our Research
      • BBCIC FDA Grants
    • Publications & Presentations
  • News & Events
    • BBCIC Calendar
    • BBCIC News
    • Quarterly Newsletters
  • Resources
    • BBCIC Resources
    • FDA Guidance
    • Biosimilars Facts
  • Search
 
Enter your keyword(s)

Breadcrumb

  1. BBCIC
  2. Resources
  3. FDA Guidance
  4. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product

Main navigation

  • About
    • About BBCIC
    • Governance
    • Partners
    • Contact
  • Research
  • News & Events
  • Resources
    • BBCIC Resources
    • FDA Guidance
    • Biosimilars Facts
  • Search

Scientific Considerations in Demonstrating Biosimilarity to a Reference Product

Scientific Considerations in Demonstrating Biosimilarity to a Reference Product is the final version of a draft guidance for industry originally released in 2012. It provides an overview of FDA’s approach to determining biosimilarity and discusses important scientific considerations for demonstrating that a proposed therapeutic protein product is biosimilar to a reference product. The document reaffirms that FDA will use a risk-based “totality of the evidence” approach to reviewing applications for biosimilar products. It also supports a stepwise approach in developing evidence to support a demonstration of biosimilarity, which can include a comparison of the proposed product and the reference product with respect to structure, function, animal toxicity, human pharmacokinetics and pharmacodynamics, clinical immunogenicity, and clinical safety and effectiveness.

Additional topics discussed include:

  • General scientific principles in conducting comparative structural analyses, functional assays, animal testing, human studies, clinical immunogenicity assessments, and comparative clinical studies.
  • Considerations of the complexities of therapeutic protein products when designing a biosimilar development program, including manufacturing process considerations.
  • Use of data derived from studies comparing a proposed biosimilar product with a non-US-licensed comparator product.
  • Postmarketing safety monitoring considerations.

The full document is available on the FDA website.

 

Tags:

Why BBCIC?
Learn more about BBCIC and what we do.
Download Our Fact Sheet
Join BBCIC
Help us monitor use, impact, safety, and clinical effectiveness of biologics including biosimilars.
Participate in BBCIC

Contact Us

Send a Message

Address

675 N Washington Street
Suite 220
Alexandria, VA 22314

Phone

703.684.2600

Menu

  • About
  • Research
  • News & Events
  • Resources
  • Search
BBCIC Logo
  • Antitrust
  • Privacy Policy
  • Disclaimer


© 2025 Biologics and Biosimilars Collective Intelligence Consortium (BBCIC)

  • About
    • About BBCIC
      • BBCIC FAQs
    • Governance
      • Board of Managing Directors
      • Communications Committee
      • Steering Committee
      • Science Committee
    • Partners
    • Contact
  • Research
    • Approach
    • Range of Research
    • Our Research
      • BBCIC FDA Grants
    • Publications & Presentations
  • News & Events
    • BBCIC Calendar
    • BBCIC News
    • Quarterly Newsletters
  • Resources
    • BBCIC Resources
    • FDA Guidance
    • Biosimilars Facts
  • Search